Neohemocyte

Neohemocytes, colloquially known as "new blood cells", represent a significant advancement in the realm of medical biotechnology. Developed by researchers at the University of California at San Francisco (UCSF), these artificial red blood cells have the potential to revolutionize blood storage and transfusion practices.

Composition and Structure

Neohemocytes are not naturally occurring entities; rather, they are synthetically crafted to mimic some of the functionalities of authentic erythrocytes, or red blood cells. Their composition can be broken down as follows:

• Hemoglobin Molecules: These are naturally occurring proteins responsible for oxygen transport in real red blood cells. In neohemocytes, these molecules are artificially encapsulated<ref>Chang, T. M. (2005). Therapeutic applications of polymeric artificial cells. Nature Reviews Drug Discovery, 4(3), 221-235.</ref>.
• Fat Bubbles: These are primarily composed of phospholipids and cholesterol. By encasing hemoglobin within these bubbles, the neohemocyte structure is achieved.
• In terms of size, neohemocytes are considerably smaller than human erythrocytes, approximating one-twelfth the dimensions of the latter.

Advantages Over Natural Red Blood Cells

A compelling advantage of neohemocytes lies in their storage longevity. Traditional erythrocytes, when stored for transfusion purposes, have a shelf-life of approximately 35 days<ref>Hess, J. R. (2006). Red cell storage. Journal of Proteomics, 73(3), 368-373.</ref>. In stark contrast, neohemocytes boast a substantially prolonged storage time of roughly six months. This extended duration has the potential to mitigate challenges associated with blood shortages and storage logistics in medical facilities.

Potential for Oxygen-Carrying Content

While current iterations of neohemocytes utilize natural hemoglobin as the oxygen-carrying entity, future developments could potentially incorporate artificial hemoglobin. Though such a technique remains in its conceptual stage and is not yet commercially available, it paves the way for myriad advancements in the domain of artificial blood product research<ref>Winslow, R. M. (2008). Current status of oxygen carriers ("blood substitutes"): 2006. Vox Sanguinis, 94(2), 87-98.</ref>.

Conclusion

The creation of neohemocytes underscores the progressive strides being made in medical biotechnology. As research continues to evolve, these artificial red blood cells may hold the key to addressing challenges associated with blood storage and transfusion. Further studies are crucial to ascertain their safety, efficacy, and broader applications in clinical settings.

References

<references />

   This article is a medical stub. You can help WikiMD by expanding it!